- Investing Ideas
- Canadian Pharmaceuticals & Biotech Healthy potentially undervalued
Canadian Pharmaceuticals & Biotech Healthy potentially undervalued
Results
9
Companies which are potentially undervalued and in an acceptable financial position.
9 companies
High Tide
Market Cap: CA$273.2m
Engages in the cannabis retail business in Canada, the United States, and internationally.
HITI
CA$3.22
7D
5.9%
1Y
-20.7%
Verano Holdings
Market Cap: CA$610.3m
Operates as a vertically integrated multi-state cannabis operator in the United States.
VRNO
CA$1.68
7D
-0.6%
1Y
-1.2%
Curaleaf Holdings
Market Cap: CA$2.3b
Produces and distributes cannabis products in the United States and internationally.
CURA
CA$3.27
7D
8.6%
1Y
42.8%
Aurora Cannabis
Market Cap: CA$256.3m
Engages in the production, distribution, and sale of cannabis and cannabis-derivative products in Canada and internationally.
ACB
CA$4.77
7D
-13.4%
1Y
-44.7%
Medexus Pharmaceuticals
Market Cap: CA$92.2m
Operates as a pharmaceutical company in Canada and the United States.
MDP
CA$2.84
7D
0.4%
1Y
-11.5%
Cresco Labs
Market Cap: CA$620.3m
Cresco Labs Inc. cultivates, manufactures, and sells retail and medical cannabis products in the United States and Germany.
CL
CA$1.43
7D
0.7%
1Y
3.6%
TerrAscend
Market Cap: CA$315.2m
TerrAscend Corp. cultivates, produces, and sells cannabis products in Canada and the United States.
TSND
CA$0.92
7D
7.0%
1Y
-1.1%
Trulieve Cannabis
Market Cap: CA$1.6b
Operates as a cannabis retailer.
TRUL
CA$9.48
7D
0.9%
1Y
39.8%
Knight Therapeutics
Market Cap: CA$579.3m
Focuses on acquiring, in-licensing, out-licensing, marketing, and commercializing prescription pharmaceutical products in Canada and Latin America.
GUD
CA$5.88
7D
1.4%
1Y
2.8%